Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 362 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... August 20, 2019 SIOG 2020: New Research in Caring for and Treating People With... November 12, 2020 EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... June 24, 2022 Cómo puede ayudar la terapia del piso pélvico a las personas... December 13, 2022 Load more HOT NEWS When Cancer Isn’t Your Only Challenge: How I Learned to Cope Trial Examines Value of Lymph Node Surgery in Advanced Ovarian Cancer ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... Air Pollution and Breast Cancer Risk – A Link That Calls...
